Table 3.
Effect of demographic, clinical and genetic factors on overall response rates, progression-free survival and overall survival in the study group
| Variable | PD 41 (45.1 %) | SD, PR 50 (54.9 %) | p, OR 95 % CI | Median PFS (mo.) | p, χ 2 | HR 95 % CI | Median OS (mo.) | p, χ 2 | HR (95 % CI) |
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Male | 31 (50.8 %) | 30 (49.2 %) | 0.1179, 0.4839 | 4 | 0.8653 | 0.9560 | 13 | 0.7280 | 1.1177 |
| Female | 10 (33.3 %) | 20 (66.7 %) | 0.1948–1.2022 | 6 | 0.0288 | 0.5684–1.6079 | 11 | 0.1210 | 0.5971–2.0923 |
| Age (years) | |||||||||
| ≤70 | 34 (46.6 %) | 39 (53.4 %) | 0.5581, 0.7299 | 3.56 | 0.6344 | 0.8719 | 11.5 | 0.7812 | 0.9061 |
| >70 | 7 (38.9 %) | 11 (61.1 %) | 0.2546–2.0929 | 0.2262 | 0.4956–1.5339 | 16.5 | 0.0772 | 0.4519–1.8169 | |
| Smoking status | |||||||||
| Smokers | 39 (45.9 %) | 46 (54.1 %) | 0.7978, 0.7863 | 47.5 | 0.5347 | 0.7441 | 11.5 | 0.8851 | 0.9187 |
| Non-smokers | 2 (40 %) | 3 (60 %) | 0.125–4.9481 | 0.3854 | 0.2926–1.8921 | 18.5 | 0.0209 | 0.2909-2.9012 | |
| Histopathological diagnosis | |||||||||
| Adenocarcinoma | 18 (40 %) | 27 (60 %) | – | 6 | 0.1356 | – | 12 | 0.6073 | – |
| Squamous cell carcinoma | 10 (71.4 %) | 4 (28.6 %) | 2 | 5.5517 | 6.5 | 1.8352 | |||
| Large cell carcinoma | 8 (47.1 %) | 9 (52.9 %) | 4 | 13 | |||||
| NOS NSCLC | 5 (33.3 %) | 10 (66.7 %) | 3.5 | 9.5 | |||||
| Adenocarcinoma | 18 (39.1 %) | 28 (60.9 %) | 0.2520, 1.6263 | 6 | 0.0456 | 0.6074 | 12 | 0.4094 | 0.7802 |
| Other | 23 (51.1 %) | 22 (48.9 %) | 0.7077–3.7371 | 3 | 3.9962 | 0.3725–0.9903 | 11.5 | 0.6805 | 0.4326–1.4071 |
| Squamous cell carcinoma | 10 (71.4 %) | 4 (28.6 %) | 0.0392, 0.2696 | 2 | 0.0140 | 0.3399 | 6.5 | 0.1807 | 0.5301 |
| Non-squamous cell carcinoma | 31 (40.3 %) | 46 (59.7 %) | 0.0776–0.9369 | 4.5 | 6.0383 | 0.1437–0.8038 | 12 | 1.7916 | 0.2093–1.3427 |
| Large cell carcinoma | 8 (50 %) | 8 (50 %) | 0.6619, 0.7857 | 3.754 | 0.4972 | 0.8030 | 13 | 0.9921 | 1.0036 |
| Other | 33 (44 %) | 42 (56 %) | 0.2666–2,3157 | 0.4608 | 0.4263–1.5128 | 11.5 | 0.0001 | 0.4928–2.0439 | |
| Stage of disease | |||||||||
| IIIB | 10 (35.7 %) | 18 (64.3 %) | 0.2348, 1.7438 | 7 | 0.0094 | 0.5212 | 18 | 0.0701 | 0.5687 |
| IV | 31 (49.2 %) | 32 (50.8 %) | 0.6968–4.3641 | 3 | 6.7519 | 0.3188–0.8520 | 10 | 3.2800 | 0.3088–1.0475 |
| Performance status | |||||||||
| PS = 0 | 2 (16.7 %) | 10 (83.3 %) | 0.0495, 4.8750 | 7.5 | 0.2694 | 0.7024 | 21 | 0.0700 | 0.5124 |
| PS ≥1 | 39 (49.4 %) | 40 (50.6 %) | 1.0031–23.691 | 3.5 | 1.2197 | 0.3752–1.3148 | 11 | 3.2831 | 0.2485–1.0562 |
| Weight loss before CTH | |||||||||
| Yes | 17 (43.6 %) | 22 (56.4 %) | 0.9567, 1.0245 | 6 | 0.7040 | 0.9058 | 18 | 0.0376 | 0.4632 |
| No | 19 (44.2 %) | 24 (55.8 %) | 0.4278–2.4538 | 3 | 0.1443 | 0.5436–1.5092 | 7.5 | 4.3237 | 0.2242–0.9568 |
| Anemia before CTH | |||||||||
| Yes | 32 (54.2 %) | 27 (45.8%) | 0.0189, 0.3302 | 3 | 0.0154 | 0.5430 | 11 | 0.3844 | 0.7685 |
| No | 9 (28.1 %) | 23 (71.9 %) | 0.1309–0.8329 | 6.5 | 5.8656 | 0.3313–0.8901 | 13 | 0.7565 | 0.4246–1.3910 |
| Side effect after CTH | |||||||||
| Yes | – | – | – | 4.5 | 0.3008 | 0.7515 | 12 | 0.3435 | 0.7231 |
| No | 4 | 1.0706 | 0.4374–1.2911 | 21 | 0.8974 | 0.3697–1.4142 | |||
| Subsequent lines of treatment | |||||||||
| Yes | – | – | – | 5 | 0.7157 | 0.9131 | 16.5 | 0.0305 | 0.5011 |
| No | 3 | 0.1326 | 0.5596–1.4897 | 8 | 4.6802 | 0.2680–0.9371 | |||
| Family history of cancer (any malignant) | |||||||||
| Yes | 6 (33.3 %) | 12 (66.7 %) | 0.3367, 1.7500 | 3.5 | 0.8389 | 0.9349 | 7.5 | 0.4320 | 0.7412 |
| No | 21 (46.7 %) | 24 (53.3 %) | 0.5588–5.4810 | 3 | 0.0413 | 0.4887–1.7885) | 11.5 | 0.6175 | 0.3511–1.5645 |
| RRM1 (−37C>A) | |||||||||
| AA | – | 5 (100 %) | – | 10.5 | 0.0986 | – | 18.5 | 0.0677 | – |
| AC | 23 (47.9 %) | 25 (52.1 %) | 4 | 4.6330 | 18 | 5.3846 | |||
| CC | 15 (42.9 %) | 20 (57.1 %) | 3.5 | 9.5 | |||||
| AA | – | 5 (100 %) | 0.1352, 9.3077 | 10.5 | 0.0437 | 2.1736 | 18.5 | 0.8528 | 1.1004 |
| AC or CC | 38 (45.7 %) | 45 (54.3 %) | 0.4986–173.75 | 3.5 | 4.0687 | 1.0222–4.6220 | 11.5 | 0.0344 | 0.4006–3.0223 |
| AC | 23 (47.9 %) | 25 (52.1 %) | 0.3270, 0.6522 | 44 | 0.7840 | 1.0707 | 18 | 0.0351 | 1.9088 |
| AA or CC | 15 (37.5 %) | 25 (62.5 %) | 0.2775–1.533 | 0.0751 | 0.6569–1.7452 | 11 | 4.4381 | 1.0460–3.4833 | |
| CC | 15 (42.9 %) | 20 (57.1 %) | 0.9601, 1.0222 | 3.5 | 0.0928 | 1.5613 | 9.5 | 0.0193 | 2.1346 |
| AA or AC | 23 (43.3 %) | 30 (56.7 %) | 0.4316–2.4208 | 5.5 | 2.8249 | 0.9286–2.6251 | 18 | 5.4786 | 1.1312–4.0281 |
| RRM1 (−524C>T) | |||||||||
| CC | 1 (14.3 %) | 6 (85.7 %) | – | 10.5 | 0.0923 | – | 18.5 | 0.4129 | – |
| CT | 24 (50 %) | 24 (50 %) | 3.5 | 4.7664 | 11.5 | 1.7691 | |||
| TT | 16 (44.4 %) | 20 (55.6 %) | 3.5 | 10 | |||||
| CC | 1 (14.3 %) | 6 (85.7 %) | 0.1237, 5.4545 | 10.5 | 0.0343 | 2.1249 | 18.5 | 0.5983 | 1.2875 |
| CT or TT | 40 (47.6 %) | 44 (52.4 %) | 0.6291–47.293 | 3.5 | 4.4805 | 1.0574–4.2700 | 11 | 0.2776 | 0.5029–3.2959 |
| CT | 24 (50 %) | 24 (50 %) | 0.3174, 0.6538 | 3.5 | 0.9141 | 0.9740 | 11.5 | 0.3318 | 0.7505 |
| CC or TT | 17 (39.5 %) | 26 (60.5 %) | 0.2843–1.504 | 6 | 0.0116 | 0.6035–1.5720 | 11 | 0.9417 | 0.4204–1.3399 |
| TT | 25 (45.4 %) | 30 (54.6 %) | 0.9246, 0.9600 | 3.5 | 0.0983 | 1.5342 | 10 | 0.1807 | 1.5055 |
| CT or CC | 16 (44.4 %) | 20 (55.6 %) | 0.4124–2.2347 | 4 | 2.7336 | 0.9237–2.5484 | 13 | 1.7920 | 0.8270–2.7404 |